Literature DB >> 21534541

Antineoplastic agents. 592. Highly effective cancer cell growth inhibitory structural modifications of dolastatin 10.

George R Pettit1, Fiona Hogan, Steven Toms.   

Abstract

The dolastatin series of unique peptides, originally discovered as constituents of the sea hare Dolabella auricularia, is of increasing importance in providing biological leads, especially to new and useful anticancer drugs. Dolastatin 10 and three analogues, minor structural modifications designated auristatins, are currently in human cancer clinical trials. The present study was undertaken to explore delivery to the cancer sites by way of phosphate or quinoline modifications. The initial objectives, auristatin TP as sodium phosphate 3b (GI50 10(-2)-10(-4) μg/mL), auristatin 2-AQ (4, GI50 10(-2)-10(-3) μg/mL), and auristatin 6-AQ (5, GI50 10(-4) μg/mL), exhibited superior cancer cell growth inhibitory properties.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21534541      PMCID： PMC3116808          DOI： 10.1021/np1007334

Source DB:  PubMed          Journal:  J Nat Prod        ISSN： 0163-3864            Impact factor:   4.050


  33 in total

1.  Isolation and Bioactivity of 2-Aminoquinoline from Leucopaxillus albissimus.

Authors:  J R Pfister
Journal:  J Nat Prod       Date:  1988-09       Impact factor: 4.050

2.  Synthesis and biological evaluation of novel 6-nitro-5-substituted aminoquinolines as local anesthetic and anti-arrhythmic agents: molecular modeling study.

Authors:  Fatma E Goda; Alaa A-M Abdel-Aziz; Hamdy A Ghoneim
Journal:  Bioorg Med Chem       Date:  2005-05-02       Impact factor: 3.641

3.  Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs.

Authors:  G R Pettit; J W Lippert
Journal:  Anticancer Drug Des       Date:  2000-06

4.  Antineoplastic agents 365. Dolastatin 10 SAR probes.

Authors:  G R Pettit; J K Srirangam; J Barkoczy; M D Williams; M R Boyd; E Hamel; R K Pettit; F Hogan; R Bai; J C Chapuis; S C McAllister; J M Schmidt
Journal:  Anticancer Drug Des       Date:  1998-06

5.  Development of potent monoclonal antibody auristatin conjugates for cancer therapy.

Authors:  Svetlana O Doronina; Brian E Toki; Michael Y Torgov; Brian A Mendelsohn; Charles G Cerveny; Dana F Chace; Ron L DeBlanc; R Patrick Gearing; Tim D Bovee; Clay B Siegall; Joseph A Francisco; Alan F Wahl; Damon L Meyer; Peter D Senter
Journal:  Nat Biotechnol       Date:  2003-06-01       Impact factor: 54.908

Review 6.  Primaquine revisited six decades after its discovery.

Authors:  Nuno Vale; Rui Moreira; Paula Gomes
Journal:  Eur J Med Chem       Date:  2008-09-11       Impact factor: 6.514

7.  Auristatin PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour models.

Authors:  Steven D Shnyder; Patricia A Cooper; Nicola J Millington; G Robert Pettit; Michael C Bibby
Journal:  Int J Oncol       Date:  2007-08       Impact factor: 5.650

8.  Differential gene expression in auristatin PHE-treated Cryptococcus neoformans.

Authors:  Tanja Woyke; Michael E Berens; Dominique B Hoelzinger; George R Pettit; Günther Winkelmann; Robin K Pettit
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

9.  Antineoplastic agents. 511. Direct phosphorylation of phenpanstatin and pancratistatin.

Authors:  George R Pettit; Noeleen Melody; Delbert L Herald
Journal:  J Nat Prod       Date:  2004-03       Impact factor: 4.050

10.  Antitumor activity of TZT-1027, a novel dolastatin 10 derivative.

Authors:  M Kobayashi; T Natsume; S Tamaoki; J Watanabe; H Asano; T Mikami; K Miyasaka; K Miyazaki; M Gondo; K Sakakibara; S Tsukagoshi
Journal:  Jpn J Cancer Res       Date:  1997-03
View more
  8 in total

1.  Antineoplastic agents. 548. Synthesis of iodo- and diiodocombstatin phosphate prodrugs.

Authors:  George R Pettit; Heidi J Rosenberg; Rachel Dixon; John C Knight; Ernest Hamel; Jean-Charles Chapuis; Robin K Pettit; Fiona Hogan; Brandy Sumner; Kenneth B Ain; Brindi Trickey-Platt
Journal:  J Nat Prod       Date:  2012-02-10       Impact factor: 4.050

2.  Total synthesis and cytotoxicity of the marine natural product malevamide D and a photoreactive analog.

Authors:  Werner Telle; Gerhard Kelter; Heinz-Herbert Fiebig; Peter G Jones; Thomas Lindel
Journal:  Beilstein J Org Chem       Date:  2014-02-03       Impact factor: 2.883

Review 3.  Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates.

Authors:  David J Newman; Gordon M Cragg
Journal:  Mar Drugs       Date:  2017-03-29       Impact factor: 5.118

Review 4.  Cyanobacteria as Natural Therapeutics and Pharmaceutical Potential: Role in Antitumor Activity and as Nanovectors.

Authors:  Hina Qamar; Kashif Hussain; Aishwarya Soni; Anish Khan; Touseef Hussain; Benoît Chénais
Journal:  Molecules       Date:  2021-01-05       Impact factor: 4.411

Review 5.  Cyanobacterial Metabolite Calothrixins: Recent Advances in Synthesis and Biological Evaluation.

Authors:  Su Xu; Bhavitavya Nijampatnam; Shilpa Dutta; Sadanandan E Velu
Journal:  Mar Drugs       Date:  2016-01-12       Impact factor: 5.118

6.  Palladium-Catalyzed Dehydrogenative Coupling: An Efficient Synthetic Strategy for the Construction of the Quinoline Core.

Authors:  Asier Carral-Menoyo; Verónica Ortiz-de-Elguea; Mikel Martinez-Nunes; Nuria Sotomayor; Esther Lete
Journal:  Mar Drugs       Date:  2017-08-30       Impact factor: 5.118

7.  Identification and Characterization of a Novel Protein ASP-3 Purified from Arca subcrenata and Its Antitumor Mechanism.

Authors:  Zhongyi Guo; Hui Shi; Chunlei Li; Yuanyuan Luo; Sixue Bi; Rongmin Yu; Haoran Wang; Wanying Liu; Jianhua Zhu; Weijuan Huang; Liyan Song
Journal:  Mar Drugs       Date:  2019-09-09       Impact factor: 5.118

Review 8.  Marine Antitumor Peptide Dolastatin 10: Biological Activity, Structural Modification and Synthetic Chemistry.

Authors:  Gang Gao; Yanbing Wang; Huiming Hua; Dahong Li; Chunlan Tang
Journal:  Mar Drugs       Date:  2021-06-24       Impact factor: 5.118
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.